Loading...
XSHG
688488
, Last price  
Name

Jiangsu Aidea Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:688488 chart
P/E
—
P/S
—
EPS
0.02
Vol. 1Y
—
Shs. 5Y
-0.15%
Rev. 5Y
20.05%
Div Yld LY
—
Div Yld TTM
—
Revenues
721m
+72.49%
257,842,256136,264,416276,905,636345,225,157289,056,180255,709,508244,219,269411,363,845417,804,701720,669,600
Net income
8m
P
14,236,868-37,986,5378,617,89033,648,94139,771,790-29,985,624-124,093,296-76,069,539-141,204,2968,083,067
CFO
18m
P
31,288,2160056,195,15056,168,65400-166,224,919-37,497,78917,631,500
Dividend
Jun 24, 20210.048 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Aidea Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and commercialization of diverse pharmaceutical products. Its extensive offerings encompass a range of medications including folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules. The company also provides pharmaceutical raw materials. Established in 2009, Jiangsu Aidea Pharmaceutical is headquartered in Yangzhou, China.
IPO date
Jul 20, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT